ClinicalTrials.gg
Not yet recruitingNCT07156500Updated Sep 5, 2025

A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone

A Phase 3 interventional study of HS-20094 Injection and HS-20094 Placebo Injection in Type 2 Diabetes, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited — 2 open to participants now, 2 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Hansoh Pharmaceutical Group Company Limited.

Planned enrollment
5th of 12
204 · median 61
Started
2025
with 1 other
Phase 3
4 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 3, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of HS-20094 injection in subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise alone. The primary objective of this study is to evaluate the effectiveness of HS-20094 compared to placebo in controlling blood glucose levels after 44 weeks and 52 weeks treatment.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, Age ≥18 years at the time of signing .
  2. Diagnosed with type 2 diabetes mellitus (T2DM) for at least 90 days prior to day of screening.
  3. Treatment with Diet and Exercise alone at least 90 days prior to day of screening.
  4. 7.5% ≤ ≤10.5% at screening.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrollable hypertension(with or without antihypertensive treatment) : systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at screening.
  2. Diagnosed or suspected with type 1 diabetes mellitus, special types of diabetes or secondary diabetes.
  3. History of significant hematological disorders (e.g., sickle cell disease, hemolytic anemia, myelodysplastic syndrome, etc.) or other conditions causing hemolysis or instability of red blood cells (e.g., malaria, hypersplenism, etc.).
  4. Presence of an endocrine disorder or history that may significantly affect bady weight(e.g., Cushing's syndrome, hypothyroidism or hyperthyroidism, except hypothyroidism if thyroid hormone replacement dose has been stable for at least 6 months) ;
  5. Severe infection, severe trauma, or moderate-to-major surgery within 4 weeks before screening.
  6. Participated in clinical trials of any drug or medical device within 12 weeks prior to screening, and participation in clinical trials is defined as signing and using drugs (including placebo) or investigational medical devices; Or is still in the trial drug within 5 half-lives (whichever is Longer).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    Group A

    Drug: HS-20094 Injection

  • Placebo comparator
    Group B

    Drug: HS-20094 Placebo Injection

  • Experimental
    Group C

    Drug: HS-20094 Injection

  • Placebo comparator
    Group D

    Drug: HS-20094 Placebo Injection

Interventions

  • HS-20094 injected subcutaneously once weekly

  • DrugHS-20094 Placebo Injection

    HS-20094 Placebo injected subcutaneously once weekly

  • HS-20094 injected subcutaneously once weekly

  • DrugHS-20094 Placebo Injection

    HS-20094 Placebo injected subcutaneously once weekly

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change from baseline in HbA1c after 44 weeks of treatment

    Time frame: Week 0 to Week 44

Secondary outcomes

  1. Proportion of subjects with HbA1c<7.0% and ≤6.5%

    Proportion of subjects with HbA1c\<7.0% and ≤6.5% after 44 weeks of treatment

    Time frame: Week 0 to Week 44

  2. Change in FPG

    Change from baseline in FPG after 44 weeks of treatment

    Time frame: Week 0 to Week 44

  3. Change in body weight

    Change from baseline in Change in body weight after 44 weeks of treatment

    Time frame: Week 0 to Week 44

  4. Proportion of subjects with weight loss ≥5% and ≥10%

    Proportion of subjects with weight loss ≥5% and ≥10% after 44 weeks of treatment

    Time frame: Week 0 to Week 44

  5. Change in HbA1c

    Change from baseline in HbA1c after 52 weeks of treatment

    Time frame: Week 0 to Week 52

  6. Proportion of subjects with HbA1c<7.0% and ≤6.5%

    Proportion of subjects with HbA1c\<7.0% and ≤6.5% after 52 weeks of treatment

    Time frame: Week 0 to Week 52

  7. Change in FPG

    Change from baseline in FPG after 52 weeks of treatment

    Time frame: Week 0 to Week 52

  8. Change in body weight

    Change from baseline in Change in body weight after 52 weeks of treatment

    Time frame: Week 0 to Week 52

  9. Proportion of subjects with weight loss ≥5% and ≥10%

    Proportion of subjects with weight loss ≥5% and ≥10% after 52 weeks of treatment

    Time frame: Week 0 to Week 52

  10. Incidence and severity of adverse events

    Severity (mild, moderate and severe) is assessed by investigator

    Time frame: Week 0 to Week 52+4 weeks follow-up

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Mar 2027, 18 months later.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 5, 2025
StartEst.
Sep 30, 2025
Primary completionEst.
Mar 30, 2027
CompletionEst.
May 30, 2027
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07156500
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Sep 30, 2025 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Sep 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-20094

Start the discussion